AXNX News and Press, Axonics Modulation Technologies Inc. From 07/26/22

ShockWave’s disruptive approach within the calcified cardiovascular disease space creates a first-mover advantage offering the opportunity of robust sales growth. ShockWave Medical’s business model looks to “Grow Markets and Take Market Share” targeting an ...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report second quarter 2022 financial results after the close of trading on Monday, August 1. Axonics will ...

Axonics (NASDAQ:AXNX) said it filed a premarket approval supplement with the FDA for its fourth generation rechargeable sacral neuromodulation implantable neurostimulator (INS). The fourth gen rechargeable INS reduces the time needed by a patient to recharge their implanted device to onc...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has filed a premarket approval supplement with the FDA for its fourth generation rechargeable sacral neuromodulatio...

Axonics is a high-growth medical device play with strong revenue growth drivers. The company’s rechargeable SNM system generates the vast majority of its sales. Long-term investors can buy the company’s shares during pullbacks to maximize their gain. For furthe...

Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In what turned out to be a challenging first quarter, Baron Discovery Fund (the “Fund”) decreased 16.30% (I...

Axonics, Inc. (AXNX) Q1 2022 Earnings Conference Call May 5, 2022 04:30 PM ET Company Participants Neil Bhalodkar - Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - President & Chief Financial Officer Conference Call Participants Adam Maeder - Piper Sandler Cecilia ...

Axonics Modulation Technologies press release (NASDAQ:AXNX): Q1 GAAP EPS of -$0.50 beats by $0.13. Revenue of $48.42M (+40.9% Y/Y) beats by $3.05M. FY22 Outlook: Total company revenue of $238M, an increase of 32% compared to FY21 revenue. This compares to prior revenue guidance of $234M;...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2022. “We are pleased with this qu...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will participate in the BofA Securities 2022 Healthcare Conference on May 10, 2022. Axonics is scheduled to pre...